An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...

Inflation-squeezed shoppers are buying less branded packaged food—or opting for alternatives like fresh bakery and produce ...

Shares of Vera Therapeutics (VERA) sold off about 20% on Friday following news in competitor Otsuka’s 2024 earnings presentation that the ...

DeepSeek hasn’t sunk Nvidia’s prospects for a big year. But more-grounded hopes should still prove advantageous to the artificial-intelligence giant as it navigates a tricky road ahead.

US-listed product tanker owners were taking on more losses in early trading Friday after a bloody Thursday that saw two top ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Business combination materially improves scale and product scope, advancing Columbus McKinnon's strategy as the holistic ...

Evercore Inc.’s EVR fourth-quarter 2024 adjusted earnings per share of $3.41 surpassed the Zacks Consensus Estimate of $2.90. Also, the bottom line compared favorably with the prior-year quarter ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

However, Evercore ISI upgraded Juniper Networks Inc. (NYSE:JNPR) to “Outperform” from “In Line” with a $40 stock price target on February 4th, as the brokerage sees two potential scenarios ...

Evercore ISI upgraded CarMax (KMX) to Outperform from In Line with a price target of $110, up from $90. The firm sees the company’s improving comp and share trends persisting amid a favorable ...